1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
6
Rare Diseases
across 15 areas
0
News (30d)
Quiet
Cav-Con, Inc. is a company with 1 orphan drug designation across 6 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Fanconi anemia | Microbubble contrast agent | Des.TrialAppr. |
| chromosome 15q26-qter deletion syndrome | Microbubble contrast agent | Des.TrialAppr. |
| holoprosencephaly-radial heart renal anomalies syndrome | Microbubble contrast agent | Des.TrialAppr. |
| infantile hemangioma of rare localization | Microbubble contrast agent | Des.TrialAppr. |
| intraoperative floppy iris syndrome | Microbubble contrast agent | Des.TrialAppr. |
| megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome | Microbubble contrast agent | Des.TrialAppr. |
50% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio
50% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio